JANUMET®

Drug Information Related Patent

Hold Company

MSD SUB MERCK

Learn More

Dosage and Administration

TABLET;ORAL

Specification

500MG; EQ 50MG BASE
1GM；EQ 50MG BASE

Indication

JANUMET® can be used as auxiliary diet and exercise, so as to improve the adult type Ⅱ the glycemic control of diabetic patients.

Use

Instructions for Use

API

METFORMIN HYDROCHLORIDE
SITAGLIPTIN PHOSPHATE

API Structure

We Supply

METFORMIN HYDROCHLORIDE

Note:

CP/BP/EP/JP/USP
Facility GMP
Product GMP
ASMF/USMF/US-FDA/KFDA/WHO/CEP/KDMF

SITAGLIPTIN PHOSPHATE

Note:

EP/USP/In-house Standard/IP/CP
Facility GMP
ASMF/USMF/NMPA DMF/DMF/CDE

null

Note:

null

Drug Patent

Patent No	Expiration Date
7326708	2026/11/24
7326708*PED	2027/5/24
8414921	2028/7/21
8414921*PED	2029/1/21

API Patent

Patent No	Expiration Date
7326708	2026/11/24

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION